carnitine has been researched along with HIV-Associated Lipodystrophy Syndrome in 1 studies
HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-carnitine is a nonessential micronutrient that regulates fatty acid transport into the mitochondrial matrix for metabolism via beta-oxidation." | 2.42 | Acetyl-L-carnitine for the treatment of HIV lipoatrophy. ( Day, L; Gerschenson, M; Shikuma, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Day, L | 1 |
| Shikuma, C | 1 |
| Gerschenson, M | 1 |
1 review available for carnitine and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Acetyl-L-carnitine for the treatment of HIV lipoatrophy.
Topics: Acetylcarnitine; Carnitine; Fatty Acids; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Huma | 2004 |